Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21866586 | 0.89 | RAPGEF4 (0.43) | RAPGEF4ALPLALPICRHR1ALDH1A1 | |
| SCHEMBL18299263 | 0.75 | ALPL (0.43) | ALPLALPIALDH1A1LMNA | |
| SCHEMBL3222871 | 0.73 | LMNA (0.36) | ALPLALPIALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL21866613 | 0.71 | ALDH1A1 (0.42) | ALPLALPICRHR1ALDH1A1LMNA | |
| SCHEMBL11315683 | 0.69 | GAA (0.43) | ALDH1A1LMNA | |
| SCHEMBL11273856 | 0.68 | MEN1 (0.51) | ALDH1A1LMNA | |
| SCHEMBL9345965 | 0.67 | ALDH1A1 (0.35) | ALPLALPIALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18308288 | 0.67 | RAPGEF4 (0.53) | RAPGEF4ALDH1A1 | |
| SCHEMBL31497276 | 0.64 | TGM2 (0.53) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18299613 | 0.63 | FFAR4 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10106501-B2 | Nuclear receptor modulators | ABBVIE INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3307734-A1 | NUCLEAR RECEPTOR MODULATORS | AbbVie Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016198908-A1 | ROR NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016198908-A1 | ROR NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | RAPGEF4 1471/4885ALPL 2187/4885ALPI 1083/4885 |
| US-10106501-B2 | Nuclear receptor modulators | NR1I2, NR1H2, NR5A2 | RAPGEF4 1471/4885ALPL 2187/4885ALPI 1083/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | RAPGEF4 1471/4885ALPL 2187/4885ALPI 1083/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | RAPGEF4 1471/4885ALPL 2187/4885ALPI 1083/4885 |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | RAPGEF4 1471/4885ALPL 2187/4885ALPI 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.